Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND Study

Le H Hua¹, Amit Bar-Or², Fred D Lublin³, Xiangyi Meng⁴, Gina Mavrikis Cox⁴, Bruce AC Cree⁵, Robert J Fox⁶

¹Lou Ruvo Center for Brain Health, Las Vegas, NV; ²Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Icahn School of Medicine at Mount Sinai, New York, NY; ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ; ⁵Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; ⁶Cleveland Clinic, Cleveland, OH

Poster number: 002 (Neighborhood 4) Session name: P5 (MS Clinical Trials and Therapeutics 1) Session time: Sunday, April 3, 11:45 AM - 12:45 PM

Poster Presentation at the American Academy of Neurology (AAN) 2022, April 2-7, 2022



Scan to download a copy of this presentation

Disclosures

Author Name	Disclosures				
Le Hua	Received personal fees for speaking, consulting and advisory board activities from Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Novartis, TG Therapeutics, Horizon, Greenwich, Alexion. Received research support from Biogen paid directory to her institution.				
Amit Bar-Or	Participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from: Atara Biotherapeutics, Biogen Idec, Celgene/Receptos, Janssen/Actelion, MAPI, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech and Sanofi-Genzyme.				
Fred D Lublin	Received personal compensation for consulting from AbbVie, Acorda Therapeutics, Actelion, Apitope, Atara Biotherapeutics, Bayer, Biogen, Brainstorm Cell Therapeutics, EMD Serono, Forward Pharma, Innate Immunotherapeutics, Mapi Pharma, MedDay Pharma, MedImmune, Novartis, Orion Biotechnology, Polpharma, Receptos/Celgene, Regeneron, Roche Genentech, Sanofi Genzyme, Teva Neuroscience and TG Therapeutics; and research support from Actelion, NMSS, Novartis Pharmaceuticals Corporation, Sanofi, Teva Neuroscience and Transparency Life Sciences. He has also received personal compensation as an editor for Multiple Sclerosis and Related Disorders.				
Xiangyi Meng and Gina Mavrikis Cox	Employees of Novartis Pharmaceuticals Corporation.				
Bruce AC Cree	Received personal compensation for consulting from Akili, Alexion, Atara, Biogen, EMD Serono, Novartis and TG Therapeutics.				
Robert J Fox	Received personal fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis and Teva; grants from Novartis; and other support from Biogen and Novartis (clinical trial contracts).				

Funding source: The study was supported by Novartis Pharmaceuticals Corporation.

Acknowledgments: Editorial support was provided by **Juliel Espinosa**, **PhD**, of Alphabet Health (New York, NY) and was funded by Novartis Pharmaceuticals Corporation. This poster was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this poster.

Background

- For patients with relapsing forms of multiple sclerosis (RMS), risk of transitioning to secondary progressive MS (SPMS) remains high, despite treatment availability¹
- Siponimod (Mayzent®) is a selective sphingosine 1-phosphate receptor (S1P1 and S1P5) modulator, approved in the USA for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting MS, and active SPMS²
- Increasing age is associated with disability accumulation, independent of MS duration, and may negatively affect treatment outcomes³
- In EXPAND, a phase 3 trial examining the efficacy and safety of siponimod in an SPMS population, siponimod significantly reduced risk of confirmed disability progression (CDP) versus placebo⁴
- We investigated efficacy and safety of siponimod in the subpopulation of patients from EXPAND with active SPMS (relapse in 2 years before screening and/or ≥1 T1 Gd+ lesion at baseline), in line with approved indication of Siponimod, and compared by age subgroups²

Objective

 Assess efficacy and safety of siponimod in patients with active SPMS in subgroups of patients aged <50 and ≥50 years at Baseline from the EXPAND study

Gd+, gadolinium-enhancing.

1. University of California SFMSET, et al. Ann Neurol. 2016;80:499-510. 2. Novartis Pharmaceuticals Corporation. Prescribing information. Mayzent® 2019. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mayzent.pdf (Accessed May 1, 2019). 3. Scalfari A, et al. Neurology. 2011;77:1246-1252. 4. Kappos L, et al. Lancet. 2018;391:1263-1273.





Study design

 EXPAND was a phase 3, 36 month, randomized, placebocontrolled trial of siponimod 2 mg/day in adults (18-60 years) with SPMS, EDSS score of 3.0-6.5, and EDSS progression in the 2 years before study¹

Analyses

- Post hoc analyses were performed in subgroups of patients aged <50 and ≥50 years at Baseline with active SPMS (≥1 relapse in the 2 years before Baseline and/or ≥1 T1 Gd+ lesion at Baseline)
- Proportional hazard model was used in the analysis of time to 3- and 6-month CDP (as per EDSS scores)
- Number and percentage of patients with AEs were reported
- Analyses for hypothesis generation only

Patient Disposition

- EXPAND included 1651 patients (siponimod, n=1105; placebo, n=546)
- Of these, 779 patients had active SPMS and were stratified by median baseline age:
 - <50 years, 471 patients (siponimod, n=326; placebo, n=145)
 - ≥50 years, 308 patients (siponimod, n=190; placebo, n=118)

AE, adverse event; CDP, confirmed disability progression; EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; SPMS, secondary progressive multiple sclerosis. 1. Kappos L, et al. Lancet. 2018;391:1263-1273.




CDP in the overall active SPMS subpopulation of EXPAND, and baseline age subgroups

- In the phase 3 EXPAND trial, for overall subpopulation with active SPMS, siponimod reduced risk of:
 - o 3-month CDP by 31% (p=0.0094)
 - 6-month CDP by 37% (p=0.0040)
- In patients <50 years, siponimod reduced risk of:
 - 3-month CDP by 31% versus placebo (siponimod, 27%; placebo, 36%; p=0.0383)
 - 6-month CDP by 38% (siponimod, 21%; placebo, 32%; p=0.0126)
- In those ≥50 years, siponimod reduced the risk of:
 - 3-month CDP by 38% versus placebo (siponimod, 22%; placebo, 33%; p=0.0332)
 - 6-month CDP by 37% (siponimod, 16%; placebo, 24%; p=0.0749)

placebo, 24%; p=0.0749) CDP, confirmed disability progression; CI, confidence interval; HR, hazard ratio; SPMS, secondary progressive multiple sclerosis.






Results: Safety

L. Hua et al. P5.002

AE frequency in the overall EXPAND population, and baseline age subgroups

- The safety profile of siponimod in EXPAND was generally similar in the overall population and among baseline age subgroups
- · Siponimod was generally well tolerated in both age subgroups
 - <50 years: rates of any AE were similar for siponimod and placebo (85.6% vs 80.0%)
 - ≥50 years: rates of any AE were slightly higher for siponimod than placebo (88.9% vs 76.3%)
- In both age subgroups, rates of serious AEs were slightly lower for siponimod than placebo
 - <50 years: siponimod, 14.1% vs placebo, 15.9%
 - ≥50 years: siponimod, 18.9% vs placebo, 20.3%
- Rates of AEs leading to discontinuation were slightly higher in those aged ≥50 years than <50 years
 - \circ $\,$ <50 years: siponimod, 5.2% vs placebo, 6.2% $\,$
 - ≥50 years: siponimod, 6.8% vs placebo, 5.9%



Conclusions





Background & Objective

Methods



Proportion of patients (%)

AEs associated with siponimod in the overall EXPAND population, and baseline age subgroups

 Proportionally more patients receiving siponimod than placebo experienced AEs previously associated with S1Preceptor modulation irrespective of baseline age

Event	Overall Population		<50 years			≥50 years	
n (%)	Siponimod (n=1099)	Placebo (n=546)	Siponimod (n=326)	Placebo (n=145)		Siponimod (n=190)	Placebo (n=118)
Bradycardia	48 (4.4)	14 (2.6)	30 (9.2)	7 (4.8)		7 (3.7)	3 (2.5)
Hypertension	137 (12.5)	50 (9.2)	32 (9.8)	8 (5.5)		29 (15.3)	11 (9.3)
Lymphopenia	9 (0.8)	0	4 (1.2)	0		0	0
Macular edema	18 (1.6)	1 (0.2)	3 (0.9)	0		4 (2.1)	1 (0.8)
Herpes zoster	25 (2.3)	4 (0.7)	5 (1.5)	0		4 (2.1)	1 (0.8)

AE, adverse event; N, number of patients; n, number of observations; S1P, sphingosine 1-phosphate;

Background & Objective Methods Conclusions



- Siponimod provided similar clinical benefits in reducing CDP risk in patients aged <50 years and ≥50 years with active SPMS
- Siponimod was generally well tolerated by patients with active SPMS, regardless of baseline age
- These results are consistent with the overall active SPMS cohort in EXPAND¹



CDP, confirmed disability progression; SPMS, secondary progressive multiple sclerosis. 1. Gold R, et al. Presented at ECTRIMS 2019; abstract P750.

Background & Objective Methods Results Conclusions

